JP Morgan Chase
DMAC icon

JP Morgan Chase’s DiaMedica Therapeutics DMAC Stock Holding History

JP Morgan Chase’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Buy
15,193
+877
+6% +$5.39K ﹤0.01% 5975
2026
Q1 		$95.1K Buy
14,316
+757
+6% +$6K ﹤0.01% 5863
2025
Q4 		$108K Buy
13,559
+774
+6% +$5.79K ﹤0.01% 5840
2025
Q3 		$87.8K Buy
12,785
+302
+2% +$1.64K ﹤0.01% 5971
2025
Q2 		$48.7K Buy
+12,483
New +$48.7K ﹤0.01% 5937
2024
Q4 		– Sell
-27
Closed -$113 – 7448
2024
Q3 		$113 Buy
+27
New +$100 ﹤0.01% 6983
2024
Q1 		– Sell
-564
Closed -$1.6K – 7495
2023
Q4 		$1.6K Buy
564
+539
+2,156% +$1.33K ﹤0.01% 6752
2023
Q3 		$65 Buy
25
+4
+19% +$13 ﹤0.01% 6959
2023
Q2 		$91 Buy
+21
New +$51 ﹤0.01% 6705
2021
Q3 		– Sell
-8,299
Closed -$37K – 6537
2021
Q2 		$37K Buy
+8,299
New +$68K ﹤0.01% 5813
2020
Q4 		– Sell
-8
Closed – – 5689
2020
Q3 		$0 Hold
8
– – ﹤0.01% 5528
2020
Q2 		$0 Buy
+8
New +$36 ﹤0.01% 5436

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase's DMAC Position: Q2 2026 in Review

JP Morgan Chase increased its DiaMedica Therapeutics (DMAC) stake by 6.1% in Q2 2026, buying an estimated $5.39K and bringing the position to 15,193 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #5975.

JP Morgan Chase first reported a position in DMAC in Q2 2020 and has held it in 12 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • JP Morgan Chase held 15,193 shares of DiaMedica Therapeutics worth $110K as of Q2 2026.
  • JP Morgan Chase bought 877 DiaMedica Therapeutics shares in Q2 2026, an estimated $5.39K.
  • DiaMedica Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5975 holding.
  • JP Morgan Chase first reported a position in DiaMedica Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.